Market Insights: Neurocrine Biosciences, Inc. (NBIX)’s Notable Gain of 1.71, Closing at 138.48

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

As of close of business last night, Neurocrine Biosciences, Inc.’s stock clocked out at $138.48, up 1.71% from its previous closing price of $136.15. In other words, the price has increased by $1.71 from its previous closing price. On the day, 0.64 million shares were traded. NBIX stock price reached its highest trading level at $138.73 during the session, while it also had its lowest trading level at $134.81.

Ratios:

To gain a deeper understanding of NBIX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.68. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.11.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on April 24, 2024, Upgraded its rating to Overweight and sets its target price to $170 from $140 previously.

On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $136.Deutsche Bank initiated its Buy rating on December 12, 2023, with a $136 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 06 ’24 when Delaet Ingrid sold 273 shares for $140.55 per share. The transaction valued at 38,370 led to the insider holds 7,507 shares of the business.

BENEVICH ERIC sold 19,818 shares of NBIX for $2,643,020 on Apr 15 ’24. The Chief Commercial Officer now owns 40,778 shares after completing the transaction at $133.36 per share. On Apr 01 ’24, another insider, Delaet Ingrid, who serves as the Chief Regulatory Officer of the company, sold 272 shares for $137.30 each. As a result, the insider received 37,346 and left with 7,507 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 13936210944 and an Enterprise Value of 13136343040. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 38.07, and their Forward P/E ratio for the next fiscal year is 20.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.03 while its Price-to-Book (P/B) ratio in mrq is 5.84. Its current Enterprise Value per Revenue stands at 6.628 whereas that against EBITDA is 26.651.

Stock Price History:

Over the past 52 weeks, NBIX has reached a high of $148.37, while it has fallen to a 52-week low of $89.04. The 50-Day Moving Average of the stock is 0.36%, while the 200-Day Moving Average is calculated to be 11.98%.

Shares Statistics:

It appears that NBIX traded 851.20K shares on average per day over the past three months and 742600 shares per day over the past ten days. A total of 98.70M shares are outstanding, with a floating share count of 98.08M. Insiders hold about 2.54% of the company’s shares, while institutions hold 92.84% stake in the company. Shares short for NBIX as of 1714435200 were 1827288 with a Short Ratio of 2.15, compared to 1711584000 on 2426109. Therefore, it implies a Short% of Shares Outstanding of 1827288 and a Short% of Float of 2.1300000999999997.

Earnings Estimates

The stock of Neurocrine Biosciences, Inc. (NBIX) is currently drawing attention from 18.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of $1.05 for the current quarter, with a high estimate of $1.62 and a low estimate of $0.27, while EPS last year was $0.95. The consensus estimate for the next quarter is $1.26, with high estimates of $1.51 and low estimates of $0.91.

Analysts are recommending an EPS of between $5.51 and $3.11 for the fiscal current year, implying an average EPS of $4.12. EPS for the following year is $6.26, with 19.0 analysts recommending between $8.52 and $4.78.

Revenue Estimates

In the current quarter, 25 analysts expect revenue to total $547.37M. It ranges from a high estimate of $581M to a low estimate of $532M. As of the current estimate, Neurocrine Biosciences, Inc.’s year-ago sales were $447.31MFor the next quarter, 25 analysts are estimating revenue of $568.91M. There is a high estimate of $619M for the next quarter, whereas the lowest estimate is $553M.

A total of 27 analysts have provided revenue estimates for NBIX’s current fiscal year. The highest revenue estimate was $2.37B, while the lowest revenue estimate was $2.17B, resulting in an average revenue estimate of $2.22B. In the same quarter a year ago, actual revenue was $1.89BBased on 27 analysts’ estimates, the company’s revenue will be $2.6B in the next fiscal year. The high estimate is $3.78B and the low estimate is $2.32B.

Most Popular

[the_ad id="945"]